Kornimate/medical-research-clean huggingface dataset:
study of the cytokine response during exercise dyspnea in patients with chronic obstructive pulmonary disease (copd). effect of body composition

Conditions: Chronic Obstructive Pulmonary Disease Severe; Dyspnea

Summary: dyspnea, more commonly known as breathlessness, is a symptom found in the majority of patients with chronic obstructive pulmonary disease (copd), with a major impact on quality of life and mortality. copd is a chronic inflammatory disease of the bronchi, affecting 8% of the french population (more than 3 million people). by 2030, it will be the third leading cause of death worldwide. effective management of dyspnea in these patients is a priority. in patients with severe copd, physical exertion increases the workload of breathing, leading to dyspnea. at the same time, the respiratory muscles and fatty cells release cytokines, myokines and adipokines - a group of proteins involved in the inflammatory response. in addition, 15% of copd patients suffer from sarcopenia (loss of muscle mass and strength) which increases respiratory effort and dyspnea. our research project aims to study the effect of dyspnea relief in copd patients on cytokine, myokine and adipokine levels, taking into account the presence of sarcopenia. indeed, it is possible to alleviate the workload of the respiratory muscles during exercise by means of respiratory assistance. the ultimate goal is a better understanding of dyspnea mechanisms, to enable the development of cytokine-targeted therapies and improve quality of life and survival in these patients.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient affiliated to a social security scheme. * patient capable of giving free, informed, written and signed consent. * male gender * severe copd (chronic obstructive pulmonary disease) diagnosed according to gold criteria, in a stable state, with a forced expiratory volume (fev1) from 30 to 50% of the predicted value (measured within one year during respiratory function tests (rft) * history of smoking \>10 pack-years with cessation of smoking for more than 12 months. * patient judged by the investigator to be able to tolerate inspiratory pressure during a preliminary cycling exercise test. exclusion criteria: * severe anxiety disorders, assessed by the stay y-b form questionnaire; a score above 65 indicates very high day-to-day anxiety. * patient under guardianship/trusteeship/supervision of justice * chronic hypercapnia at rest (co2 arterial pressure ≥ 50mmhg) * chronic use of non-invasive ventilation * known pulmonary hypertension * chronic administration of oral corticosteroids * unstable heart disease

Keywords: cytokines myokines adipokines exercise noninvasive ventilation sarcopenia
bnp testing in patients with sob on presentation to ed

Conditions: Heart Failure, Congestive

Summary: a trial to examine whether a new heart failure blood test can improve the outcome of patients presenting to the emergency department with shortness of breath. we hypothesise that a bnp test performed in real-time in patients presenting to the emergency department with shortness of breath will help identify additional patients with chf and consequently to change practice and allow more patients to recieve correct treatment earlier.

in recent years new tests to diagnose heart failure have become available. we are evaluating a new test called b-type natriuretic peptide(bnp)in patients presenting to the emergency department with shortness of breath. patients are randomised into whether they will receive the new test or not. in the patient group where the test is positive, standardised approach that will optimise heart failure treatment will be introduced. we hypothesise that with this approach we will improve the clinical care of patients who present to the emergency department with shortness of breath. measures of outcomes will be the accuracy of diagnosis 2 hours after presentation, 30 day mortality, hospital and icu admission rates and quality of life at 30days. we plan to investigate 600 consecutive patient presenting to the to the emergency department with shortness of breath that are over 40 years old and present with an emergency department triage category of 3 or higher. patients presenting with a traumatic cause of dyspnea, patients with severe renal disease, patients with cardiogenic shock and patients who have early transfer to another hospital(within 24 hrs) will be excluded.

Eligibility criteria:
inclusion criteria: we plan to include all patients presenting to the ed with shortness of breath that are over 40 years old and present with an emergency department triage category of 3 or higher. exclusion criteria: patients presenting with a traumatic cause of dyspnea, patients with severe renal disease (serum creatinine level of more than 250 micro mmol/l, patients with cardiogenic shock, and patients who have an early transfer to another hospital (within 24 hrs) will be excluded.

Keywords: atrial natriuretic factor. biochemistry. cardiac failure. randomised trials. hormones. systolic heart failure. diastolic heart failure. ischaemic cardiomyopathy. ventricular hypertrophy. ami
are the pancreatic serum proteins pancreatic stone protein (psp) and pancreatitis-associated protein (pap) predictive for the development of sepsis? retrospective study in trauma patients with soft tissue defects.

Conditions: Trauma Patients With Soft Tissue Defects

Summary: retrospective analysis of psp- and pap-serum levels in trauma patients with soft tissue defects and possible correlation with the incidence and onset of infection and sepsis.


Eligibility criteria:
inclusion criteria: * trauma patients submitted to the university hospital zurich, aged 18-65 with soft tissue defects exclusion criteria: * patients with known immunocompromising illnesses, drug abuse or infectious diseases.
non-invasive measurement of sjvo2 using near infrared spectroscopy in critically ill patients

Conditions: Impaired Oxygen Delivery; Critically Ill Patient

Summary: scvo2 is an important parameter in the management of critically ill patient. the only way to measure it is to have an internal jugular or subclavian central venous catheter. with this trial, the investigators want to show a positive relationship between invasive scvo2 measurement and noninvasive sjvo2 measurement with vo 100 medical device from mespere lifesciences, allowing the use of sjvo2 as a noninvasive surrogate of scvo2 in critically ill patients.

scvo2 measures central venous oxygen saturation level from veins draining the head and upper body while svo2 measures mixed venous oxygen saturation from the lower and upper half of the body. scvo2 is more conveniently measured and less risky than sv02 measurement although a central venous catheter is needed. scvo2 gives knowledge about the balance between the delivery of oxygen and oxygen consumption in the body. interest in scvo2 monitoring in anesthesia and critical care has been debated. however, scvo2 is still recommended as a major hemodynamic target of early resuscitation of critically ill patients. even if scvo2 measurement is far less invasive than svo2 measurement through pulmonary artery catheter, it is accompanied with morbidity. vo 100 medical device from mespere lifesciences allows a non-invasive measurement of sjvo2 using the nirs technique. jugular venous oxygen saturation (sjvo2) is a measurement of the amount of oxygen left in the venous system after the brain has removed the oxygen that it needs. on the same principle that a positive relationship between scvo2 and svo2 has been shown, what the investigators are trying to do is to show a positive relationship between sjvo2 and scvo2 in order to possibly use in the future sjvo2 measured by vo 100 as a noninvasive surrogate of scvo2.

Eligibility criteria:
inclusion criteria: * all icu adult patients routinely equipped with a central venous catheter placed in internal jugular or subclavian vein allowing scvo2 measurement from blood sampling. the investigators will perform this study only on patients already equipped with an internal jugular cvc. in other words, the placement of the cvc is not conditioned by the study realization. exclusion criteria: * patients with cvc placed in another site than internal jugular vein.

Keywords: brain oxygen delivery jugular venous oxygen saturation central venous oxygen saturation medical device use
effect of anaca3 slimming gel on loss of abdominal and thigh circumferences in healthy volunteers

Conditions: Overweight and Obesity

Summary: overweight and obesity is defined, according to the world health organization (who), by abnormal or excessive accumulation of adipose or fatty tissue that may be harmful to health. overweight and obesity are therefore important determinants of health, which expose people to many pathologies whose consequences for individuals are not only health, but also social: stigma, prejudice, discrimination. indeed, most overweight people have a bad image of themselves. for some people, overweight can trigger stress, malaise and disgust. to break free from this malaise and satisfy the growing desire of women to take care of their body, many products are present in the slimming beauty market. effanaca3gel is a prospective, randomized, double-blind, placebo controlled study. 208 healthy volunteers will be followed for 2 months during which they will use anaca3 slimming gel. the aim of this study is to evaluate the effects of anaca3 slimming gel on hip and waist circumferences.


Eligibility criteria:
inclusion criteria: * healthy woman, * age between 18 and 65 years, * body mass index (bmi) strictly greater than 23 kg / m² and strictly less than 35 kg / m² with a stable weight (± 2 kg) for at least 3 months, * stable physical activity for at least 3 months, * lack of firmness in the abdomen and thighs, * presenting cellulite visible in the thighs, with a score of 3 to 8 according to the photographic scale used, * hormonal treatment not modified for at least 3 months, * informed and written consent signed. exclusion criteria: * pregnant or lactating woman, * use of a slimming product and / or anti-cellulite (oral or topical) in the month prior to participating in the study, * slimming diet during the last 3 months, * special diet: low calorie diet (slimming diet and / or medication taken with or without a significant increase in physical activity over the last 3 months) or special diet (vegetarians, vegans, any intake of nutritional supplements ) * smoking (more than 3 cigarettes per day) and/ or addiction to alcohol, * consuming more than 3 cups of coffee and / or tea per day, * active evolutionary pathology or a history of cancer, * under corticosteroids or any other medicinal treatment that may have an influence on water retention without therapeutic balance at the time of inclusion, * antecedent of surgery for bariatric and / or aesthetic, * severe eating disorders (anorexia, bulimia, binge eating, etc.), * not affiliated to a social security scheme.

Keywords: overweight obesity slimming gel cosmetic product waist circumference thigh circumference
the effect of spontaneous respiration on pulse-oximetry measurements

Conditions: Chronic Respiratory Disease; COPD; Interstitial Lung Disease

Summary: this is a study designed to measure, characterize and describe changes on pulse-oxymetry values produced as a result of deep breaths in patients with stable chronic hypoxemic respiratory failure.

there is no standard way of measuring rest pulse-oxymetry in terms of depth of respiration. rest pulse-oxymetry values are used in the clinical setting to make therapeutic decisions regarding the need of supplemental oxygen. the primary goal of this study is to measure the change of pulse-oxymetry values during an experimental protocol of 10 deep breaths during one minute in patients with chronic hypoxemia. 45 patients will be studied in this first phase. in a second phase, secondary goals will be to measure vd/vt vent, noninvasive cardiac output and ct densitometry during the same deep breaths protocol in a subset of 13 patients with the grater increase observed in the first phase of study.

Eligibility criteria:
inclusion criteria: * patients with chronic lung disease causing rest hypoxemia, with rest spo2 values equal or lower than 94% on room air * ambulatory patients capable of performing 6 min walking test * patients older than 18 years old. exclusion criteria: * patients with significant collagen disease causing raynaud phenomenon. * patients with hypothermia lower than 35 degrees celsius * patients with rest spo2 values equal or lower than 80% on room air * patients unable to perform pfts * patients unable to complete 6 min walking test without supp o2. * patients unable to perform experimental deep breaths on ct scan

Keywords: pulseoxymetry capnography dead space cardiac output lung recruitment deep breaths
a study of nivolumab or nivolumab plus experimental medication bms-986205 with or without bacillus calumette-guerin (bcg) in bcg unresponsive bladder cancer that has not invaded into the muscle wall of the bladder

Conditions: Urinary Bladder Neoplasms

Summary: a study to evaluate the safety and tolerability of nivolumab or nivolumab plus bms-986205 with or without bcg in bcg-unresponsive non-muscle invasive bladder cancer.


Eligibility criteria:
inclusion criteria: * pathologically demonstrated bcg-unresponsive, carcinoma in situ (cis)-containing high-risk non-muscle-invasive bladder cancer (nmibc) defined as cis with or without papillary component * participants must have cis to be eligible. * predominant histologic component (\> 50%) must be urothelial (transitional cell) carcinoma * eastern cooperative oncology group (ecog) performance status 0-1 exclusion criteria: * sign of locally advanced disease or metastatic bladder cancer * urothelial cancer (uc) in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment * prior immuno-oncology therapy other protocol-defined inclusion/exclusion criteria apply

Keywords: bladder cancer bcg-unresponsive nivolumab intravesical bcg nmibc non-muscle invasive bms-986205 checkmate 9ut
prophylactic treatment of travellers' diarrhoea with rifaximin

Conditions: Diarrhoea

Summary: the aim of the study is to investigate the efficacy of the prophylactic treatment with rifaximin to prevent travellers diarrhoea.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 and \< 65 years * good general condition (according to history and clinical examination) * written informed consent * no pregnancy * no breast feeding * efficacious contraception (e.g. oral, double-barrier) during the study and 4 weeks after termination of the study * no participation in other clinical trials 4 weeks before, during participation, and 4 weeks after participation in this study * planned travel period between 6 and 28 days * planned travel to south- and southeast asia * planned time to arrival in south- or southeast asia ≤ 24 hours exclusion criteria: * pregnancy * breast feeding * age \< 18 and ≥ 65 years * no written informed consent * chronic gastrointestinal disease and/ or immune insufficiency * low general condition (according to history and clinical examination) * regular medication with gastrointestinal side-effects and/or immunosuppressive medication * participation in other clinical trials 4 weeks before, during and 4 weeks after termination of the study * no efficacious contraception * planned travel period \ 28 days * planned travel outside south- and southeast asia * vaccination against cholera using dukoral within 12 months prior to inclusion * planned time to arrival in south- or southeast asia \> 24 hours * known hypersensitivity against rifaximin or rifamycin-derivatives in general * known lactose intolerance

Keywords: traveller's diarrhoea prevention
soluble b7-h3 as a biomarker for osteosarcoma

Conditions: Biomarker; Progression; Osteosarcoma; Surveillance

Summary: increasing data has indicated an association between increased soluble b7-h3 (sb7-h3) levels and unfavorable prognosis in patients with malignancies. however, the level of sb7-h3 and its clinical significance in osteosarcoma are not well known. in this present study, we investigated whether sb7-h3 levels in serum could be as a biomarker for osteosarcoma treatment.


Eligibility criteria:
inclusion criteria: * high grade osteosarcoma verified with pathologic diagnosis. * systemic treatment-naive before the first time blood drawing. * ecog 0 or 1 and all the other imagings indicate that patients could tolerate standard pkuph-os-02 protocol neoadjuvant chemotherapy. * all radiographs are complete for clinical evaluation. exclusion criteria: * patients who can't tolerate blood drawing. * patients without complete medical records in pkuph system. * patients who can't tolerate pkuph-os-02 neoadjuvant chemotherapy. * other conditions that investigators think are not suitable for this study.

Keywords: sb7-h3 osteosarcoma biomarker prognosis clinical evaluation
effects of berberine hydrochloride and bifidobacterium in prediabetes prevention and treatment

Conditions: Prediabetes

Summary: the aim of this study is to assess the beneficial effects of bifidobacterium and berberine hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

gut microbiota may play an important role in patients with prediabetes. berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. therefore, the aim of this study is to assess the beneficial effects of bifidobacterium and berberine hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities * male or female between 18 and 70 years of age * 19≤body mass index(bmi)≤30kg/m2 * no participate in any clinical trial at least 3 months * fasting blood glucose(fbg)\<7.0mmol/l and 2-hour postprandial blood glucose(2hpbg)\<11.1mmol/l * females in child-bearing period should be given birth control * no severe disease about heart, lung and kidney * ability and willingness to adhere to the protocol including performance of self-monitored blood glucose (smbg) profiles according to the protocol; * subject is likely to comply with the investigators instruction. exclusion criteria: * type 2 diabetes mellitus or type 1 diabetes mellitus * females of childbearing potential who are pregnant，breastfeeding or intend to become pregnant or are not using adequate contraceptive methods * impaired liver function, defined as aspartate aminotransferase(ast) or alanine transaminase(alt)\> 2 times upper limit of normal (central laboratory) * impaired renal function, defined as serum-creatinine≥133μmol/l * uncontrolled treated/untreated severe hypertension (systolic blood pressure≥160mmhg and /or diastolic blood pressure≥95mmhg) * chronic gastrointestinal diseases * cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer) * any clinically significant disease or disorder, which in the investigator's opinion could interfere with the results of the trial * mental incapacity, psychiatric disorder, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read and write * previous participation in this trial. participation is defined as randomized. re-screening of screening failures is allowed only once within the limits of the recruitment period * known or suspected hypersensitivity to trial products or related products * known or suspected abuse of alcohol, narcotics or illicit drugs.

Keywords: prediabetes berberine hydrochloride bifidobacterium
a gene transfer therapy to evaluate the safety and efficacy of delandistrogene moxeparvovec (srp-9001) following therapeutic plasma exchange (plasmapheresis) in participants with duchenne muscular dystrophy (dmd) and pre-existing antibodies to aavrh74

Conditions: Duchenne Muscular Dystrophy

Summary: this is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory male participants with dmd and pre-existing antibodies to aavrh74 over a period of 58 weeks.


Eligibility criteria:
inclusion criteria: * ambulatory per protocol specified criteria. * has a definitive diagnosis of dmd prior to screening based on documentation of clinical findings and prior confirmatory genetic testing. * ability to cooperate with motor assessment testing. * has elevated aavrh74 antibody titers per protocol-specified requirements. * a pathogenic frameshift mutation, nonsense mutation or premature stop codon or pathogenic variant in the dmd gene that is expected to lead to absence of dystrophin protein with exception of a mutation in exon 8 and/or 9. * stable daily dose of oral corticosteroids for at least 12 weeks prior to screening, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight). exclusion criteria: * has reduced left ventricular ejection fraction on the screening echo or clinical signs and/or symptoms of cardiomyopathy. * presence of any other clinically significant illness, including cardiac, pulmonary, hepatic, renal, hematologic, immunologic, or behavioral disease, or infection or malignancy or concomitant illness or requirement for chronic drug treatment that in the opinion of the investigator creates unnecessary risks for gene transfer or a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the participant's ability to comply with the protocol required testing or procedures or compromise the participant's wellbeing, safety, or clinical interpretability. * exposure to gene therapy, investigational medication, or other protocol-specified treatment within the protocol specified time limits. * abnormality in protocol-specified diagnostic evaluations or laboratory tests. . note: other inclusion or exclusion criteria could apply.

Keywords: gene-delivery dmd ambulatory pediatric duchenne seropositive pre-existing antibodies aavrh74 antibody plasmapheresis titer seropositivity
devilbiss autoadjust with smartflex comparative study

Conditions: Obstructive Sleep Apnea

Summary: there will be equivalent therapeutic effectiveness between smartflex and standard modes when using the devilbiss autoadjust device.


Eligibility criteria:
inclusion criteria: * epworth sleepiness scale \>10 * body mass index \> 26 * apnea-hypopnea index (ahi) ≥15 (mod to severe range) * ahi ≤ 10 at therapeutic continuous positive airway pressure (cpap) pressure * cpap naïve patients * polysomnogram (psg) within 3 months of enrollment * average oxygen saturation by pulse oximetry (spo2) \> 90% during titration * sleep efficiency on titration night ≥ 78% exclusion criteria: * diagnosis of mild obstructive sleep apnea (osa) * co-morbid conditions which render participation to be at risk these may include patients with congestive heart failure, chronic obstructive pulmonary disease (copd) or psychiatric illness * allergies to mask materials * difficulties with nasal breathing * evidence of another primary sleep disorder * evidence of arousing periodic limb movements during titration * contraindications as listed on product labeling. * pregnant * currently diagnosed with depression if symptomatic * predominately central sleep apnea * deemed medically unsuitable by investigator * evidence of any type of infection or treatment of an infectious condition during the period of research participation * full face mask during titration * have a bi-level requirement * cpap pressure \>15cmh2o * subjects with tracheotomy * uncontrolled hypertension * require supplemental oxygen * stimulants, major tranquillizers or antipsychotics.

Keywords: autoadjust smartflex apnea hypopnea index patient reported outcomes